Reproductive Clinics Face Title X Funding Cliff on March 31

• The NYC Health Department issued an advisory confirming the first severe mpox clade I case in a city resident, marking the initial detection of this more virulent strain in New York. • Mpox clade I is one of two main genetic groups of the virus, known for causing more severe illness compared to clade II. • This development raises concerns for public health monitoring and response in urban areas amid ongoing global mpox transmission risks.

• Federal grant funding for FQHCs stayed flat from 2019-2023 while health care costs rose over 25%, leading to negative margins of 2.1% by 2024. • An estimated 11.8 million Americans will lose Medicaid coverage due to $344 billion cuts over the next decade, overwhelming FQHCs with uninsured patients. • Recent closures include a New Hampshire rural site in 2025 and six South Carolina locations last year due to shortfalls.

• On March 13, 2026, the EPA proposed repealing a 2024 Biden administration rule limiting ethylene oxide emissions from commercial sterilizer facilities, which sterilize about half of U.S. medical devices like heart valves and pacemakers. • The rule aimed to reduce cancer risks to nearby communities but is criticized for threatening domestic supply chains and relying on flawed risk models, per the Trump administration. • Ethylene oxide debate pits public health protections against medical supply reliability, with evidence suggesting alternative risk assessments like Texas models better match human data.

• A federal judge in Boston on March 16, 2026, temporarily blocked U.S. health officials from reducing the number of universally recommended childhood vaccines, halting changes announced by HHS Secretary Robert F. Kennedy Jr. in January. • The ruling stems from a lawsuit by the American Academy of Pediatrics and other groups challenging cuts to flu, rotavirus, hepatitis A and B, meningitis, and RSV vaccines, with ACIP meetings postponed as a result. • Medical organizations hailed the decision as restoring science-based policy, while HHS spokesman Andrew Nixon stated 'HHS looks forward to this judge’s decision being overturned,' amid concerns over confusion and weakened protections in 30 states.

• A person with a genetic mutation linked to ALS warns that the second Trump administration's funding cuts have halted key research, including at Mass General and the ALLFTD project for FTD. • Cuts defunded ALS studies at Harvard and other universities, pausing longitudinal research and denying symptomatic patients access to trials like baricitinib at MGH. • Health Secretary Robert F. Kennedy Jr.'s policies are linked to rising measles cases, potentially overburdening diagnostics and delaying ALS treatments that take a decade to reach patients.

• Gov. Ron DeSantis' proposal to alter Florida's vaccine requirements for school children failed during the 2026 legislative session. • DeSantis promises continued efforts to pass these policies despite the setback and ongoing measles cases rising across the state. • The resolve strengthens public health debates on vaccination mandates amid disease outbreaks in Florida.

• Americans give the Trump administration credit for reducing drug costs, according to recent polling highlighted in pharma updates. • A new study shows Eliquis (apixaban) safer than Xarelto (rivaroxaban) for patients with deep vein blood clots. • Abivax denies takeover rumors from AstraZeneca amid industry consolidation talks.

• The North American family medicine services market, valued at $187 billion in 2025, is projected to reach $241 billion by 2030, growing at a 5% CAGR. • Growth drivers include expanding health insurance, rising chronic disease prevalence, demand for preventive and primary care, telehealth adoption, and integrated U.S.-Canada systems. • Preventive care segment expected to expand by $80 billion, chronic disease management by $43 billion, acute care by $16 billion, and others by $8 billion from 2025-2030.

• Telix Pharmaceuticals resubmitted its New Drug Application to the U.S. FDA on March 16, 2026, for TLX101-Px (Pixclara®), a PET imaging agent targeting gliomas in adults and pediatrics. • The agent received Orphan Drug and Fast Track designations from the FDA due to its potential to address unmet needs in post-treatment glioma management, with 18F-FET PET already in international guidelines but no U.S.-approved equivalent. • Glioblastoma multiforme (GBM), the most common aggressive primary brain cancer, affects about 22,000 new U.S. cases yearly, with recurrence nearly universal and median survival of 12-15 months post-diagnosis.

• UPMC, a major Pittsburgh health system, stopped providing gender care services to patients under age 19 approximately nine months ago, leaving local transgender teens struggling to find alternative care options. • The policy change has forced young patients like Moss Brinzer to scramble for medical services, creating significant gaps in access to gender-affirming healthcare for minors in the region. • The decision reflects broader tensions in U.S. healthcare around gender medicine for adolescents, with major health systems reassessing their policies amid ongoing national debate.

California's 2024 Proposition 1 mental health bond has failed to open ten promised treatment centers as of March 2026, despite initial assurances of rapid deployment. The California Department of Health Care Services attributed delays to permitting issues, site conditions, and supply-chain strain from President Trump's tariffs, though officials stated most construction remains on schedule. The $6.4 billion measure was designed to expand mental health treatment capacity, but the implementation setbacks raise questions about the state's ability to address its growing mental health crisis.